Patrice Denefle

This inventor holds 18 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 1 EPO patent, primarily in Gene Therapy. Top assignees: Aventis Pharma S.a., Aventis Pharmaceuticals Inc., Rhone-Poulenc Rorer S.a.. Active years: 1998-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Patrice Denefle. Retrieved from https://idiyas.com/inventor/patrice-denefle

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 18 (Patent Applications = 3)

% Patents Active = 66.7

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 1 (Patent Applications = 4)

Average Co-Inventor Count = 5.1

ph-index = 6

Forward Citations = 170(Granted Patents)

Company Filing History:

Aventis Pharmaceuticals Inc.

patents

3 out of 247

Rhone-Poulenc Rorer S.a.

patents

4. 2 out of 23

Aventis Pharmaceuticals Products Inc.

patents

5. 2 out of 1,853

National Institute of Health and Medical Research

patents

6. 1 out of 1,369

Case Western Reserve University

patents

7. 1 out of 1

Institut National Sante Et Recherche Medicale

patent

8. 1 out of 834,601

Other

patents

where one patent can have more than one assignee

Years Active: 1998-2017

Loading Chart...

Areas of Expertise:

Parkin Gene

Nuclear Factor Kappa B

Gene Therapy

Recombinant Viruses

Apolipoprotein A-I

Transgenic Rabbit

Hyperproliferative Disorders

Dyslipoproteinemias

ABCC11 Gene

Therapeutic Uses

Regulatory Nucleic Acid

Atherosclerosis

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9540693 - Mutations of the parkin gene, compositions, methods and uses (2017-01-10),

2. 8835618 - Mutations of the parkin gene (2014-09-16),

3. 8642739 - Nuclear factor κB inducing factor (2014-02-04),

4. 8623831 - Nuclear factor κB inducing factor (2014-01-07),

5. 7998667 - Mutations of the parkin gene, compositions, methods and uses (2011-08-16),

6. 7972844 - Nuclear factor κB inducing factor (2011-07-05),

7. 7378274 - Regulatory nucleic acid for the ABC1 gene, molecules modifying its activity and therapeutic uses (2008-05-27),

8. 7041497 - Nuclear factor κB inducing factor (2006-05-09),

9. 6893841 - Nucleic acids of the human ABCC11 gene, vectors containing such nucleic acids and uses thereof (2005-05-17),

10. 6814962 - Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same (2004-11-09),

11. RE38556 - Recombinant adeno viruses comprising an inserted gene encoding apolipoprotein and their use in gene therapy for dyslipoproteinemias (2004-07-13),

12. 6512161 - Transgenic rabbit that expresses a functional human lipoprotein (a) (2003-01-28),

13. 6410011 - Gene therapy for restenosis using an adenoviral vector (2002-06-25),

14. 6258596 - Variants of apolipoprotein A-I (2001-07-10),

15. 6033885 - Integrative recombinant adenoviruses, preparation thereof and (2000-03-07),

Title: Discovering the Innovations of Inventor Patrice Denefle

Introduction

Patrice Denefle is a notable inventor located in Saint Maur, France, known for his significant contributions to the field of genetic research. With an impressive portfolio of 18 patents, Denefle has made strides in understanding and addressing mutations in the parkin gene, a critical area of study for therapeutic developments.

Latest Patents

Among his latest inventions, Denefle has focused on the mutations of the parkin gene, which include nucleic acids coding for mutated or truncated forms of the human parkin gene, as well as forms comprising multiplication of exons. These innovations also encompass the corresponding proteins and antibodies associated with the parkin gene. His patents detail methods and kits for identifying mutations of the parkin gene and for evaluating compounds for therapeutic purposes. The repetition of these inventions highlights the importance of researching the parkin gene in the context of disease treatment.

Career Highlights

Patrice Denefle has carried out significant work at prominent companies such as Aventis Pharma S.A. and Aventis Pharmaceuticals Inc. His experience in these reputable organizations has undoubtedly contributed to the development of his innovative ideas and breakthroughs in genetic research.

Collaborations

Throughout his career, Denefle has collaborated with notable professionals in his field, including Patrick Benoit and Michel Perricaudet. These partnerships have likely facilitated the exchange of ideas and further advanced his research and patent development.

Conclusion

Patrice Denefle's contributions to genetic research through his inventions and patents underscore his status as an influential inventor. With a commitment to exploring the complexities of the parkin gene, Denefle's work has the potential to impact therapeutic strategies significantly, showcasing the importance of innovation in the pursuit of scientific advancements.

Profile summary based on public USPTO records.